



Epidemiology and mechanism of Frailty in dialysis patients

Chih-Chin Kao, MD, PhD

Division of Nephrology, Taipei Medical University Hospital

Associate Professor, Taipei Medical University



Trust, Moral, Universal, Hand in Hand

Outlines



- Case study
- Frailty and epidemiology
- Pathophysiology of frailty
- Characteristics of frailty in dialysis patients
- Conclusions


Case study



- A 74-year-old woman without systemic disease, developed **AKI** (RPGN, biopsy: ANCA GN s/p plasma exchange and immunosuppressives), progressed to **ESRD** s/p regular HD thrice a week since 8 yrs ago
- BH 150cm, BW 39.7kg, **BMI 17.6**
- Hb 10.9, **Alb 4.0**, Ca 9.0 P 2.6
- Med: sacubitril/valsartan 100mg qd, folic acid 1# qd, vit B complex 1# qd, CaCO₃ 1# tid with meal, rosuvastatin 10mg qd, calcitriol 0.5ug tiw, famotidine 1# bid, darbepoetin alfa 20ug QW



Cont.





- She reported less energy, and walk fewer distances as compared to before in recent 3 months
- Q1. Is she frail? How to evaluate it?
- Q2. What is the impact of frailty in dialysis patients?



Q1. WHAT IS FRAILTY AND THE EPIDEMIOLOGY OF FRAILTY IN KIDNEY DISEASE?

Introduction



- What is frailty?
 - Frailty is characterized by a decline in both physiological state and cognitive state → a combination of symptoms, including weight loss, exhaustion, low physical activity, weakness, and slow walking speed
 - Not a single organ system or disease, but rather a multisystem syndrome
- It leads to **poor quality of life**, and higher risk of hospitalization, infection, cardiovascular events, dialysis-associated complications, and death

Diagnosis



- Currently, **no universal definition of frailty** has been established
- Comprehensive geriatric assessment
 - Physical
 - Functional
 - Cognitive
 - Psychosocial

Common used diagnostic tools

TMUH



Clinical frailty scale (CFS)

Grade 4-5: mildly frail
(May need someone help)

Grade 6: moderately frail
(need someone help)

Grade 7-9: severely frail
(completely dependent)

CLINICAL FRAILTY SCALE

	1	VERY FIT	People who are robust, active, energetic and motivated. They tend to exercise regularly and are among the fittest for their age.
	2	FIT	People who have no active disease symptoms but are less fit than category 1. Often, they exercise or are very active occasionally, e.g., seasonally.
	3	MANAGING WELL	People whose medical problems are well controlled, even if occasionally symptomatic, but often not regularly active beyond routine walking.
	4	LIVING WITH VERY MILD FRAILTY	Previously "vulnerable;" this category marks early transition from complete independence. While not dependent on others for daily help, often symptoms limit activities. A common complaint is being "slowed up" and/or being tired during the day.
	5	LIVING WITH MILD FRAILTY	People who often have more evident slowing, and need help with high order instrumental activities of daily living (finances, transportation, heavy housework). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation, medications and begins to restrict light housework.
	6	LIVING WITH MODERATE FRAILTY	People who need help with all outside activities and with keeping house. Inside, they often have problems with stairs and need help with bathing and might need minimal assistance (cuing, standby) with dressing.
	7	LIVING WITH SEVERE FRAILTY	Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within ~ 6 months).
	8	LIVING WITH VERY SEVERE FRAILTY	Completely dependent for personal care and approaching end of life. Typically, they could not recover even from a minor illness.
	9	TERMINALLY ILL	Approaching the end of life. This category applies to people with a life expectancy <6 months, who are not otherwise living with severe frailty. Many terminally ill people can still exercise until very close to death.

Common used diagnostic tools

TMUH



Frailty Phenotype

Unintended Weight Loss	Exhaustion	Weakness	Slowness	Low Physical Activity
4.5 kg or more than 5% of body weight within a year	Self-Report (2 questions from the CES-D)	Jamar Handgrip dynamometer	Gait speed in meters/second (over 4 meters)	Short version of Minnesota Leisure Time Activity-Kcal/Kg
				

Robust: 0 criteria; Pre-Frail: 1-2 criteria; Frail: 3 or more criterion

Fried LP et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001; **56**: M146-56.

CGA (Comprehensive geriatric assessment)

TMUH



Problem	Assessment Tool	Result	Abnormal Value
Mental state			
1. Delirium	CAM	None	
2. Cognitive	MMSE	22	<24
3. Depression	GDS-5	0	≥2

Problem	Assessment Tool	Result	Abnormal Value
Functional status			
1. Frailty	CFS	5	≥5
2. Activities of daily living	ADL Score	9	<95
	IADL Score	5	<5
3. Mobility and gait	SARC-F	7	≥4
	Calf Circumference	25 cm	M<34, F<33
	Handgrip	24	M<28kg, F<18kg
	TUG	15 sec	>12 sec
4. Falls	Morse Fall Scale	60	>45
5. Nutrition	MNA-SF	7	<11
	Oral Problems	Yes	
	Swallowing difficulty	No	
6. Skin Risk	Pressure sore (Braden)	19	≤16
7. Vision impairment		No	
8. Hearing impairment		No	12

CGA (Comprehensive geriatric assessment)

TMUH



Problem	Assessment Tool	Result	Abnormal Value
Subjective problem			
1. Exhaustion (>3 days / wk)		Yes	
2. Memory Decline	Self-report	Yes	
3. BW loss (>5% in recent 1 yr)		No	
4. Poor appetite		No	


Case discussion with multi-disciplinary team

TMUH



Prevalence of Frailty

TMUH




HD: 30-80%

PD: 14-69%

CKD: 12-40%

Frailty with poor outcomes




Risk of mortality in patients undergoing HD between frail and non-frail patients




Q2. WHAT IS THE PATHOPHYSIOLOGY OF FRAILTY IN KIDNEY DISEASE PATIENTS?

Contributor to frailty in patients on dialysis



Risk factors and Frailty

TMUH




Pathogenesis




- Accumulation of senescent cells into multiple tissues and proinflammatory signaling → “inflammageing”
- Aging
- Inflammation
- Oxidative stress
- Malnutrition
- Protein-energy wasting (PEW)
- Dysregulation of renin-angiotensin activity
- CKD-specific factors (ex. uremia, mineral bone disease, and dialysis treatment)

Mechanisms of Frailty



Mechanisms of Frailty

TMUH






Q3. WHAT IS THE CHARACTERISTICS OF FRAILTY IN KIDNEY DISEASE PATIENTS?

CKD health trajectory

TMUH



Functional decline in CKD

TMUH



Table 3. Multivariable Logistic Regressions of Any (N = 5592), Balance (N = 5591), and Falling (N = 5590) Problems in the Past Year

Variable	Self-report a Dizziness, Balance and/or Fall Problem			Self-report a Balance Problem			Self-report a Falling Problem		
	Odds Ratio	95% CI	P-Value	Odds Ratio	95% CI	P-Value	Odds Ratio	95% CI	P-Value
CKD stage									
Normal/controls	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
Stage 3A/3B	1.54	1.29, 1.83	<.001	1.44	1.18, 1.75	<.001	1.39	1.07, 1.83	.02
Stage 4/5	2.07	1.26, 3.40	.004	1.71	1.01, 2.90	.05	1.29	0.63, 2.62	.49

Increased balance, falling issues, and slower gait found in patients with increased CKD severity and lower 25(OH)D status

Characteristics of Frailty in dialysis

- Positive association with frailty
 - Age
 - Comorbidities
 - Ca (>10.0), P (<3.5 and >6.0), iPTH (<60)
 - Beta-2-microglobulin
- Negative association with frailty
 - **Albumin**
 - **Creatinine index (dialysis-based markers of muscle mass)**

Functional status in incident HD

TMUH



Table 4. Association of Functional Status with Early Mortality After the Start of Hemodialysis.

Outcomes	Levels of Functional Disability		
	Mild/None	Moderate	Severe
<i>Death within 3 months</i>			
Number of events / Number of patients	65/3,192	239/2,935	343/1,537
Proportion, %	2.04	8.14	22.3
Risk ratio of death (95% confidence interval) †			
Univariate analysis	Reference	4.00 (1.11 to 1.60)	11.0 (8.41 to 14.3)
Case-mix adjusted	Reference	3.41 (2.59 to 4.50)	8.39 (6.42 to 11.0)
Multivariate adjusted	Reference	2.38 (1.80 to 3.10)	3.93 (2.96 to 5.22)

Increased risk of mortality if ADLs moderately to severely impaired

Available data do not suggest improvement in frailty upon initiation of dialysis; rather, the trajectory appears **higher levels of dependence in ADLs after dialysis initiation**


Semin Dial. 2013; 26(6): 690-6

PLoS One. 2016; 11(6): e0156951 27

Dialysis vintage



N = 227,136




- Japan, ESKD patients aged >50 yrs who received dialysis in 2018
- **Frailty: defined as ≥ 2 on the Eastern Cooperative Oncology Group Performance Status (ECOG PS)**
- **Bedridden status: defined as grade 4 on the ECOG PS scale**


Long-term dialysis therapy, particularly **> 30 yrs**, associated with deterioration of physical function and frailty

Dialysis vintage

TMUH



Dialysis vintage vs **Frailty**




Dialysis vintage vs **Bed-ridden**

Functional decline in incident dialysis


TMUH



- ESKD, ≥ 65 years (N = 196), geriatric assessment
- Functional decline within the first 6 months after initiating dialysis is highly prevalent



PD patients




- NTUH, prospective, PD patients (N = 337), **Frailty phenotype**
- Predictors for frailty
 - **Old age**
 - **Diabetes mellitus**
 - **Gout**
 - **Sleep disorder**

PD patients



(A) Frailty phenotype



Frail patients presented the worse outcomes (overall survival)



CONCLUSIONS

Conclusions



- Frailty is highly prevalent in dialysis patients, and it is a combination of symptoms, associated with poor outcomes
- Aging, comorbidities and CKD/dialysis complications are contributors to frailty in kidney disease patients
- Accumulation of senescent cells and inflammageing are the central roles of frailty development
- Clinical frailty scale and Frailty phenotype are commonly used diagnostic tools
- Frailty phenotype included weight loss, exhaustion, weakness, slowness, and low physical activity
- Functional decline/prone to frailty is seen as aging, CKD progression, initiation of dialysis, and increased dialysis vintage



Xin Yi Campus



Shuang Ho Campus

Thank you for your attention!



TMU Hospital



Shuang Ho Hospital



Wan Fang Hospital



Hsin Kuo Min
Hospital



Taipei Neuroscience
Institute



Taipei Cancer Center